Shanshan Gou

State Key Laboratory Of Metabolic Dysregulation & Prevention And Treatment Of Esophageal Cancer
Zhengzhou, 450000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Enhancing tumor immunotherapy with smart nanoparticles for reprogramming macrophages and blocking the CD47/Sirpα pathway.

Enhancing tumor immunotherapy with smart nanoparticles for reprogramming macrophages and blocking the CD47/Sirpα pathway.

Journal: Materials today. Bio

Published: March 20, 2025

Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials.

Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials.

Journal: NPJ vaccines

Published: July 18, 2024

Native-compound-Coupled Affinity Matrix (NCAM) in target identification and validation of bioactive compounds: Application, mechanism and outlooks.

Native-compound-Coupled Affinity Matrix (NCAM) in target identification and validation of bioactive compounds: Application, mechanism and outlooks.

Journal: Bioorganic chemistry

Published: June 08, 2023

Engineered Nanovaccine Targeting Clec9a+ Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist.

Engineered Nanovaccine Targeting Clec9a+ Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist.

Journal: Nano letters

Published: November 15, 2021

Dysfunction of the energy sensor NFE2L1 triggers uncontrollable AMPK signaling and glucose metabolism reprogramming.

Dysfunction of the energy sensor NFE2L1 triggers uncontrollable AMPK signaling and glucose metabolism reprogramming.

Journal: Cell death & disease

Published: October 15, 2021

Metformin leads to accumulation of reactive oxygen species by inhibiting the NFE2L1 expression in human hepatocellular carcinoma cells.

Metformin leads to accumulation of reactive oxygen species by inhibiting the NFE2L1 expression in human hepatocellular carcinoma cells.

Journal: Toxicology and applied pharmacology

Published: December 24, 2020

Tryptophan 2,3-dioxygenase 2 controls M2 macrophages polarization to promote esophageal squamous cell carcinoma progression via AKT/GSK3β/IL-8 signaling pathway.

Tryptophan 2,3-dioxygenase 2 controls M2 macrophages polarization to promote esophageal squamous cell carcinoma progression via AKT/GSK3β/IL-8 signaling pathway.

Journal: Acta pharmaceutica Sinica. B

Published: December 04, 2020

Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis.

Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis.

Journal: Theranostics

Published: November 25, 2020

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: September 03, 2020

Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT.

Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT.

Journal: Cell communication and signaling : CCS

Published: July 31, 2020

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.

Journal: Cell communication and signaling : CCS

Published: March 26, 2020

Dendritic Cell Targeting Peptide-Based Nanovaccines for Enhanced Cancer Immunotherapy.

Dendritic Cell Targeting Peptide-Based Nanovaccines for Enhanced Cancer Immunotherapy.

Journal: ACS applied bio materials

Published: March 18, 2019

Showing 1-12 of 12

Last Updated: 09/26/2026